Cytokeratin 5 Antibody – 165Ho

Catalog: 716503 
Clone: EP1601Y
Isotype: Rabbit IgG
Reactivity: Human*
Application: MIBI-FFPE
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

IHC: CK5 staining of FFPE human tonsil
MIBI: CK5 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)
IHC: CK5 staining of FFPE human breast
MIBI: CK5 antibody staining (cyan) of FFPE human breast, counterstained with dsDNA (magenta)
Background: Cytokeratin 5 (CK5) is part of cytoplasmic immediate filaments that make up the cytoskeleton of basal epithelial/myoepithelial cells. CK5 expression serves as an important diagnostic, prognostic and predictive marker for a variety of cancers including basal-like breast carcinoma, ovarian carcinoma, lung carcinoma and urothelial carcinoma.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage: Human FFPE: 1:100 dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

Silvia Mihaela Illie et al. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. Breast Cancer (Dove Med Press). 2018; 10: 177–194.

Corr BR et al. Cytokeratin 5-positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer. Int J Gynecol Cancer. 2015 Nov;25(9):1565-73.

* Conjugate tested on human tissue.

Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.